Home » Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC

Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC

by Darren R. Feldman, MD & Hannah Clarke | Mar 23, 2025 | Articles | 0 Comments